DUBLIN, Jan. 16, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, announced today a partnership with Von Miller, Super Bowl MVP, Denver Broncos linebacker and advocate for healthy vision, to shine a light on the millions of people living with glaucoma. As an ambassador for the 'My Glaucoma' campaign, Miller will address the misunderstandings and impact of glaucoma and encourage those with the disease, and their caregivers, to take early action. This includes going regularly to the doctor and taking medications as prescribed. Additional information can be found at www.MyGlaucoma.com.

DUBLIN, Jan. 6, 2020 /PRNewswire/ -- Allergan plc (NYSE: AGN), today announced that its Warner Chilcott and Watson subsidiaries have reached resolutions with all plaintiffs, including a class of direct purchasers, individual direct purchasers that previously opted out of the direct purchaser class, and a class of indirect purchasers of Loestrin 24 Fe and Minastrin 24 Fe, concluding the previously disclosed antitrust litigation in the U.S. District Court for the District of Rhode Island.  The settlements make no admission of wrongdoing on the part of the company and resolve the litigation that was scheduled to go to trial on January 6, 2020.

DUBLIN, Dec. 23, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application (NDA) for UBRELVY™ (ubrogepant) for the acute treatment of migraine with or without aura in adults. UBRELVY™ is the first and only orally-administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the treatment of migraine attacks once they start. Migraine is a neurological disease characterized by intermittent migraine attacks with symptoms that are often incapacitating. Migraine afflicts 31 million Americans and is the third most common disease and second leading cause of disability worldwide.

IRVINE, Calif., Dec. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company, today announced that The Allergan Foundation has awarded a total of $10 million in charitable grants in 2019. The grants were donated to more than 400 organizations in 32 states as part of The Allergan Foundation's commitment to providing a lasting and positive impact in the communities in which Allergan employees live and work. The 2019 grants bring The Allergan Foundation's total donations in its 21-year history to approximately $95 million, including $45 million since 2015.

DUBLIN, Dec. 16, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) is commemorating today the beginning of the 30^th anniversary celebration for BOTOX^® this year with the ringing of the New York Stock Exchange opening bell. Over the past 30 years, more than 100 million vials of BOTOX^® and BOTOX^® Cosmetic have been manufactured worldwide, providing a trusted and effective treatment option for various therapeutic and aesthetic uses. With two additional U.S. Food and Drug Administration (FDA) approvals this year for therapeutic indications of pediatric upper limb spasticity and pediatric lower limb spasticity, excluding spasticity caused by cerebral palsy, BOTOX^® and BOTOX^® Cosmetic now proudly hold 14 therapeutic and aesthetic indications combined, reinforcing its leadership in neurotoxin science.

DUBLIN, Dec. 4, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE I (UBR-MD-01), a robust Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the December 5^th issue of The New England Journal of Medicine (NEJM). The data from this second published pivotal trial reinforced that the acute treatment of migraine with ubrogepant, compared with placebo, led to significantly greater rates of pain freedom and freedom from the most bothersome migraine-associated symptom at two hours with both the 50 mg and 100 mg doses. If FDA-approved, ubrogepant would be the first available and approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine.

DUBLIN, Nov. 29, 2019 /PRNewswire/ -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION In accordance with Rule 2.10 of the Irish Takeover Rules, Allergan plc (NYSE: AGN) ("Allergan") confirms that, as of the close of business on November 27, 2019, Allergan's issued share capital, excluding treasury shares, consisted of 328,416,406 ordinary shares, par value US$0.0001 per share (the "Allergan Ordinary Shares"). The International Securities Identification Number (ISIN) of the Allergan Ordinary Shares is IE00BY9D5467.

DUBLIN, Nov. 19, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that positive results from ACHIEVE II (UBR-MD-02), a pivotal Phase 3 clinical trial evaluating the efficacy, safety and tolerability of ubrogepant, have been published in the November 19^th issue of The Journal of the American Medical Association (JAMA). These data reinforced that acute treatment of migraine with ubrogepant compared with placebo led to significantly greater rates of pain freedom at two hours with both the 50 mg and 25 mg doses, and freedom from the most bothersome migraine-associated symptom at two hours with the 50 mg dose. If approved, ubrogepant would potentially be the first FDA-approved small molecule, oral calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) for the acute treatment of migraine.

DUBLIN, Nov. 18, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), the maker of BOTOX^® Cosmetic, has announced the first-ever National BOTOX^® Cosmetic Day kicking off on November 20. The celebration recognizes the impact this iconic aesthetic brand, which is the #1 selling treatment of its kind¹, has had on American cultural conversation. Just in time for the holiday season, National BOTOX^® Cosmetic Day is a moment to engage loyal consumers and healthcare providers, as well as those considering treatment, in a conversation about owning their look, with fewer lines, with BOTOX^® Cosmetic. BOTOX^® Cosmetic is the only treatment of its kind that is FDA approved for temporary improvements in moderate to severe crow's feet, frown lines, and forehead lines in adults.

DUBLIN, Nov. 11, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced the U.S. Food and Drug Administration (FDA) has granted Qualified Infectious Disease Product (QIDP) Designation and Fast Track Designation for ATM-AVI (aztreonam and avibactam), for the treatment of complicated intra-abdominal infections (cIAI), complicated urinary tract infections (cUTI), and hospital-acquired bacterial pneumonia (HABP)/ventilator-associated bacterial pneumonia (VABP). ATM-AVI is an investigational, fixed-dose, intravenous combination antibiotic under development globally.